Home › Companies › ANNX

Annexon

Market cap $662M 190.8M shares (vendor count, Nov 18, 2026) × $3.47 close Nov 17, 2026 · share count from the market-data vendor, not the SEC cover page

Most recent annual filing: 2026-03-15

Catalyst timeline

6 trackedQuarter catalyst calendar →
  1. ANX1502 C1 readout2026ANX1502 C1 readout, 2026, notable
  2. ANX1502 POC readout2H 2026ANX1502 POC readout, 2H 2026, notable
  3. Tanruprubart BLA filing4Q 2026Tanruprubart BLA filing, 4Q 2026, material
  4. Vonaprument Ph3 topline1Q 2027Vonaprument Ph3 topline, 1Q 2027, thesis-defining
  5. loan covenant trial startMar 31, 2027loan covenant trial start, Mar 31, 2027, routine
  6. loan tranche corporate updateSep 30, 2027loan tranche corporate update, Sep 30, 2027, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (6 active programs)

Technology platforms

C1q Platform

Upstream classical complement inhibition platform targeting C1q, the initiating molecule of the classical complement pathway; focus areas include neuroinflammatory and autoimmune diseases such as Guillain-Barré syndrome, geographic atrophy, and generalized myasthenia gravis

Targets: C1q

Capital (as filed)

Cash
$102M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$111M Sep 30, 2026
Operating cash flow
−$48.7M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$213M cash, runway into 2028 per the update of Nov 9, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (7)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (7 calls)

Every verdict Biotech Distilled has published on Annexon, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Annexon (ANNX): Scientific Deep Dive for ANX007 and Pipeline Products Elegant C1q biology but regulatory gambles on functional endpoints and ex-US data justify watching for a better entry ahead of the binary 2H 2026 GA readout.
  2. Watch UPDATE: Annexon (ANNX) - Spring Cleaning, Shelf Registrations, and the Dilution Gap Newly filed S-3 shelf registration reintroduces dilution risk, warranting continued caution despite unchanged science.
  3. Watch UPDATE: Annexon (ANNX) - The Dilution Gun Has Fired ATM has already fired with $32.7M in Q1 sales and shelf upsized to $150M; GBS FDA pushback more explicit, but science and ARCHER II binary unchanged.
  4. Watch UPDATE: Annexon (ANNX) - The Dilution Gun Gets a Debt Silencer Oxford $200M debt facility reduces near-term dilution but concentrates downside risk; binary ARCHER II still dominates and GBS regulatory path remains murky.
  5. Watch UPDATE: Annexon (ANNX) - The Silent Killer Gets Its First Western Data FORWARD n=10 Western data is encouraging for GBS bridging but does not change the ARCHER II binary dominating equity value.
  6. Watch UPDATE: Annexon (ANNX) - The Binary Just Grew a Second Half ARCHER II adds Month 24 dual primary endpoint; Q4 2026 now delivers a DMC verdict rather than a dataset, diffusing the catalyst across multiple quarters while science remains intact.
  7. Watch UPDATE: Annexon (ANNX) - Q3 Status Check: One Option Fizzles, the Binary Holds ANX1502 sidelined to formulation lab and GBS BLA still needs FDA alignment, but ARCHER II trial execution remains clean and balance sheet is adequate into 2028.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (10 quotes from 6 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (27)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 7, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

11 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)